Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Benefits and challenges of the active immunotherapies for alzheimer’s disease

From: Active immunotherapy options for Alzheimer’s disease

Advantages

 Natural immune response

 Persistent amyloid-beta protein antibody titer levels

 Infrequent re-administrations

 Suitable for long-term therapy

 Good compliance

 Reduced cost

 Low antigen dose

 Potential polyclonal response

 Peak titers are reached gradually

 Avidity maturation of antibodies

 Reduced risk of anaphylaxis reactions

Disadvantages

Challenges

 Relies on patients’ own immune response

 Autoreactive T-cell responses need to be avoided

 An understanding of the relationship of responses to clinical outcomes is required

 Generation of antibody responses in older patients

 Development of tolerance to be avoided

 Risk of developing an autoimmune response

 Risk of developing amyloid-related imaging abnormalities

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193